Return of D4 Dopamine Receptor Antagonists in Drug Discovery

Craig W. Lindsley, Corey R Hopkins

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

The dopamine D4 receptor garnered a great deal of interest in the early 1990s when studies showed the atypical antipsychotic clozapine possessed higher affinity for D4, relative to other dopamine receptor subtypes, and that this activity might underlie the unique clinical efficacy of clozapine. Unfortunately, D4 antagonists that were developed for schizophrenia failed in the clinic. Thus, D4 fell out of favor as a therapeutic target, and work in this area was silent for decades. Recently, D4 ligands with improved selectivity for D4 against not only D1-3,5 but also other biogenic amine targets have emerged, and D4 is once again in the spotlight as a novel target for both addiction and Parkinson's disease (PD), as well as other emerging diseases. This report will review the historical data for D4, review the known D4 ligands, and then highlight new data supporting a role for D4 inhibition in addiction, PD, and cancer.

Original languageEnglish (US)
Pages (from-to)7233-7243
Number of pages11
JournalJournal of Medicinal Chemistry
Volume60
Issue number17
DOIs
StatePublished - Jan 1 2017

Fingerprint

Dopamine Antagonists
Clozapine
Drug Discovery
Parkinson Disease
Dopamine D4 Receptors
Ligands
Biogenic Amines
Dopamine Receptors
Antipsychotic Agents
Schizophrenia
Neoplasms
Therapeutics
Inhibition (Psychology)

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Return of D4 Dopamine Receptor Antagonists in Drug Discovery. / Lindsley, Craig W.; Hopkins, Corey R.

In: Journal of Medicinal Chemistry, Vol. 60, No. 17, 01.01.2017, p. 7233-7243.

Research output: Contribution to journalReview article

@article{1eb5f7dea7804133a3f176b7a719bc60,
title = "Return of D4 Dopamine Receptor Antagonists in Drug Discovery",
abstract = "The dopamine D4 receptor garnered a great deal of interest in the early 1990s when studies showed the atypical antipsychotic clozapine possessed higher affinity for D4, relative to other dopamine receptor subtypes, and that this activity might underlie the unique clinical efficacy of clozapine. Unfortunately, D4 antagonists that were developed for schizophrenia failed in the clinic. Thus, D4 fell out of favor as a therapeutic target, and work in this area was silent for decades. Recently, D4 ligands with improved selectivity for D4 against not only D1-3,5 but also other biogenic amine targets have emerged, and D4 is once again in the spotlight as a novel target for both addiction and Parkinson's disease (PD), as well as other emerging diseases. This report will review the historical data for D4, review the known D4 ligands, and then highlight new data supporting a role for D4 inhibition in addiction, PD, and cancer.",
author = "Lindsley, {Craig W.} and Hopkins, {Corey R}",
year = "2017",
month = "1",
day = "1",
doi = "10.1021/acs.jmedchem.7b00151",
language = "English (US)",
volume = "60",
pages = "7233--7243",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "17",

}

TY - JOUR

T1 - Return of D4 Dopamine Receptor Antagonists in Drug Discovery

AU - Lindsley, Craig W.

AU - Hopkins, Corey R

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The dopamine D4 receptor garnered a great deal of interest in the early 1990s when studies showed the atypical antipsychotic clozapine possessed higher affinity for D4, relative to other dopamine receptor subtypes, and that this activity might underlie the unique clinical efficacy of clozapine. Unfortunately, D4 antagonists that were developed for schizophrenia failed in the clinic. Thus, D4 fell out of favor as a therapeutic target, and work in this area was silent for decades. Recently, D4 ligands with improved selectivity for D4 against not only D1-3,5 but also other biogenic amine targets have emerged, and D4 is once again in the spotlight as a novel target for both addiction and Parkinson's disease (PD), as well as other emerging diseases. This report will review the historical data for D4, review the known D4 ligands, and then highlight new data supporting a role for D4 inhibition in addiction, PD, and cancer.

AB - The dopamine D4 receptor garnered a great deal of interest in the early 1990s when studies showed the atypical antipsychotic clozapine possessed higher affinity for D4, relative to other dopamine receptor subtypes, and that this activity might underlie the unique clinical efficacy of clozapine. Unfortunately, D4 antagonists that were developed for schizophrenia failed in the clinic. Thus, D4 fell out of favor as a therapeutic target, and work in this area was silent for decades. Recently, D4 ligands with improved selectivity for D4 against not only D1-3,5 but also other biogenic amine targets have emerged, and D4 is once again in the spotlight as a novel target for both addiction and Parkinson's disease (PD), as well as other emerging diseases. This report will review the historical data for D4, review the known D4 ligands, and then highlight new data supporting a role for D4 inhibition in addiction, PD, and cancer.

UR - http://www.scopus.com/inward/record.url?scp=85029479942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029479942&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.7b00151

DO - 10.1021/acs.jmedchem.7b00151

M3 - Review article

C2 - 28489950

AN - SCOPUS:85029479942

VL - 60

SP - 7233

EP - 7243

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 17

ER -